Literature DB >> 15618581

Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis.

P Latzin1, M Tredano, Y Wüst, J de Blic, T Nicolai, B Bewig, F Stanzel, D Köhler, M Bahuau, M Griese.   

Abstract

BACKGROUND: Auto-antibodies against granulocyte-macrophage colony stimulating factor (GM-CSF) may be central to the pathogenesis of adult sporadic pulmonary alveolar proteinosis (PAP). The role of anti-GM-CSF auto-antibodies in paediatric forms of PAP is as yet unclear.
METHODS: Anti-GM-CSF auto-antibodies were determined with the help of an antigen capture assay using serum and/or bronchoalveolar lavage (BAL) fluid from 27 patients with PAP (nine adults, 15 children, three neonates) and from 185 children with different diseases as disease controls (various pulmonary conditions and patients with malignancies).
RESULTS: Anti-GM-CSF auto-antibodies were detected in the serum of five of seven adult PAP patients. They were not found in the serum of any of the children or neonates with PAP nor in any of the disease control patients. Raised anti-GM-CSF titres were found in BAL fluid from three of four adult patients with PAP. Anti-GM-CSF auto-antibodies were detected in BAL fluid of only one of the 15 children (age at diagnosis 11 years, age at BAL 24 years) and in none of the neonates with PAP, nor in any of the disease control patients.
CONCLUSIONS: The presence of anti-GM-CSF auto-antibodies seems to define an autoimmune disease underlying most of the adult sporadic type of PAP, but age at diagnosis may cause an overlap with children in some rare instances. In most of the children and all of the neonates the anti-GM-CSF titres were not significantly increased, indicating that alternative explanations are needed for the pathogenesis of the disease in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618581      PMCID: PMC1747161          DOI: 10.1136/thx.2004.021329

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  27 in total

Review 1.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.

Authors:  P L Shah; D Hansell; P R Lawson; K B Reid; C Morgan
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Serological diagnosis of idiopathic pulmonary alveolar proteinosis.

Authors:  T Kitamura; K Uchida; N Tanaka; T Tsuchiya; J Watanabe; Y Yamada; K Hanaoka; J F Seymour; O D Schoch; I Doyle; Y Inoue; M Sakatani; S Kudoh; A Azuma; T Nukiwa; T Tomita; M Katagiri; A Fujita; A Kurashima; S Kanegasaki; K Nakata
Journal:  Am J Respir Crit Care Med       Date:  2000-08       Impact factor: 21.405

3.  GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis.

Authors:  B Bewig; X D Wang; D Kirsten; K Dalhoff; H Schäfer
Journal:  Eur Respir J       Date:  2000-02       Impact factor: 16.671

4.  Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency.

Authors:  L M Nogee; S E Wert; S A Proffit; W M Hull; J A Whitsett
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

5.  Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.

Authors:  U Dirksen; R Nishinakamura; P Groneck; U Hattenhorst; L Nogee; R Murray; S Burdach
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis.

Authors:  J F Seymour; J J Presneill; O D Schoch; G H Downie; P E Moore; I R Doyle; J M Vincent; K Nakata; T Kitamura; D Langton; M C Pain; A R Dunn
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

Review 7.  Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review.

Authors:  B Mahut; C Delacourt; P Scheinmann; J de Blic; T M Mani; J C Fournet; G Bellon
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

8.  Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis.

Authors:  J F Seymour; C G Begley; U Dirksen; J J Presneill; N A Nicola; P E Moore; O D Schoch; P van Asperen; B Roth; S Burdach; A R Dunn
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

9.  Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice.

Authors:  J A Huffman; W M Hull; G Dranoff; R C Mulligan; J A Whitsett
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

View more
  18 in total

1.  Autoimmune pulmonary proteinosis in a Chilean teenager, a rare aetiology of interstitial lung disease.

Authors:  Alexis Strickler; Maria Lina Boza; Andres Koppmann; Sergio Gonzalez
Journal:  BMJ Case Rep       Date:  2014-05-23

Review 2.  [Interstitial processes of the lungs in childhood].

Authors:  H Popper
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

Review 3.  An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.

Authors:  Geoffrey Kurland; Robin R Deterding; James S Hagood; Lisa R Young; Alan S Brody; Robert G Castile; Sharon Dell; Leland L Fan; Aaron Hamvas; Bettina C Hilman; Claire Langston; Lawrence M Nogee; Gregory J Redding
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

Review 4.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

5.  Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis.

Authors:  F-C Lin; G-D Chang; M-S Chern; Y-C Chen; S-C Chang
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

6.  Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.

Authors:  Spyros A Papiris; Panagiotis Tsirigotis; Likurgos Kolilekas; Georgia Papadaki; Andriana I Papaioannou; Christina Triantafillidou; Anastasia Papaporfyriou; Anna Karakatsani; Konstantinos Kagouridis; Matthias Griese; Effrosyni D Manali
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

Review 7.  Rare lung disease II: pulmonary alveolar proteinosis.

Authors:  Stephen C Juvet; David Hwang; Thomas K Waddell; Gregory P Downey
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

8.  Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis.

Authors:  Francesco Bonella; Shinichiro Ohshimo; Cai Miaotian; Matthias Griese; Josune Guzman; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

9.  Congenital pulmonary alveolar proteinosis.

Authors:  Saber Hammami; Khaled Harrathi; Khaled Lajmi; Samir Hadded; Chebil Ben Meriem; Mohamed Néji Guédiche
Journal:  Case Rep Pediatr       Date:  2013-04-27

10.  Whole lung lavage of nine children with pulmonary alveolar proteinosis: experience in a tertiary lung center.

Authors:  Radpay Badiozaman; Parsa Tahereh; Dabir Shideh; Boloursaz Mohammadreza; Arbab Ahmadreza; Tabatabaei Seyyedahmad
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.